摘要
Object: This work explains the theoretical basis of </span><span style="font-family:Verdana;">“Hanshi Zufei Decoction”</span><span style="font-family:""><span style="font-family:Verdana;"> for the treatment of Coronavirus Disease 19 (COVID-19) through Western </span><span style="font-family:Verdana;">medical theories. Methods: We analyze the guideline of the “Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia” (Version I to Version VII) made by China, “Clinical</span></span><span style="font-family:""> </span><span style="font-family:Verdana;">Management of Severe Acute Respiratory Infection When Novel Coronavirus (2019-nCoV) Infection is</span><span style="font-family:""> </span><span style="font-family:Verdana;">Suspected—Interim </span><span style="font-family:Verdana;">Guidance” made by WHO, “Therapeutic Guidelines: Gastroenteropathy Section (Version V of Original)” and “Therapeutic Guidelines: Antibiotics Section (Version XV of Original)” published by Australia, and the origin of classical prescription of “Hanshi Zufei Decoction”: “Shanghan Lun (Treatise on Febrile Diseases)”, “Jinkui Yaolue (Synopsis of Golden Chamber)” and “Wenyi Lun (Treatise on Plague). We search the dictionary of traditional Chinese medicine (Version II) manually. Literature </span><span style="font-family:Verdana;">is</span><span style="font-family:Verdana;"> searched from 2001 to 2020 on </span><span style="font-family:Verdana;">the </span><span style="font-family:Verdana;">Wiley online library. We conduct a comparative study on the traditional Chinese medicine</span><span style="font-family:""> </span><span style="font-family:""><span style="font-family:Verdana;">(TCM) syndromes of </span><a name="OLE_LINK47"></a><span style="font-family:Verdana;">“Hanshi Zufei Decoction”, the pathogenesis and clinical manifestations of respiratory system diseases and acute gastrointestinal inflammation by COVID-19. And we conduct the pharmacological inquiry of </span><span style="font-family:Verdana;"></span><span style="font-family:Verdana;">“Hanshi Zufei Decoction”. Results: The respiratory and gastrointestinal symptoms of COVID-19 and the basis of the “Hanshi Zufei Decoction” are basically considered to be consistent. “Hanshi Zufei Decoction” can relieve respiratory symptoms, protect gastrointestinal mucosa, promote intestinal emptying, and have anti-inflammatory and antibacterial effects in the form of clusters. The dosage form and dosage used are in line with the range of pharmacological activity of the drug. Conclusions: “Hanshi Zufei Decoction” may have a good performance in reducing toxicity and controlling inflammation through intestinal emptying, and may play an active role in the treatment of COVID-19.
Object: This work explains the theoretical basis of </span><span style="font-family:Verdana;">“Hanshi Zufei Decoction”</span><span style="font-family:""><span style="font-family:Verdana;"> for the treatment of Coronavirus Disease 19 (COVID-19) through Western </span><span style="font-family:Verdana;">medical theories. Methods: We analyze the guideline of the “Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia” (Version I to Version VII) made by China, “Clinical</span></span><span style="font-family:""> </span><span style="font-family:Verdana;">Management of Severe Acute Respiratory Infection When Novel Coronavirus (2019-nCoV) Infection is</span><span style="font-family:""> </span><span style="font-family:Verdana;">Suspected—Interim </span><span style="font-family:Verdana;">Guidance” made by WHO, “Therapeutic Guidelines: Gastroenteropathy Section (Version V of Original)” and “Therapeutic Guidelines: Antibiotics Section (Version XV of Original)” published by Australia, and the origin of classical prescription of “Hanshi Zufei Decoction”: “Shanghan Lun (Treatise on Febrile Diseases)”, “Jinkui Yaolue (Synopsis of Golden Chamber)” and “Wenyi Lun (Treatise on Plague). We search the dictionary of traditional Chinese medicine (Version II) manually. Literature </span><span style="font-family:Verdana;">is</span><span style="font-family:Verdana;"> searched from 2001 to 2020 on </span><span style="font-family:Verdana;">the </span><span style="font-family:Verdana;">Wiley online library. We conduct a comparative study on the traditional Chinese medicine</span><span style="font-family:""> </span><span style="font-family:""><span style="font-family:Verdana;">(TCM) syndromes of </span><a name="OLE_LINK47"></a><span style="font-family:Verdana;">“Hanshi Zufei Decoction”, the pathogenesis and clinical manifestations of respiratory system diseases and acute gastrointestinal inflammation by COVID-19. And we conduct the pharmacological inquiry of </span><span style="font-family:Verdana;"></span><span style="font-family:Verdana;">“Hanshi Zufei Decoction”. Results: The respiratory and gastrointestinal symptoms of COVID-19 and the basis of the “Hanshi Zufei Decoction” are basically considered to be consistent. “Hanshi Zufei Decoction” can relieve respiratory symptoms, protect gastrointestinal mucosa, promote intestinal emptying, and have anti-inflammatory and antibacterial effects in the form of clusters. The dosage form and dosage used are in line with the range of pharmacological activity of the drug. Conclusions: “Hanshi Zufei Decoction” may have a good performance in reducing toxicity and controlling inflammation through intestinal emptying, and may play an active role in the treatment of COVID-19.
作者
Jingjing Yang
Hualiang Chen
Jingjing Yang;Hualiang Chen(Department of Pharmacy, Shaoxing Seventh People’s Hospital, Shaoxing, Zhejiang Provence, China)